136 related articles for article (PubMed ID: 33171156)
1. DYNLL1 is hypomethylated and upregulated in a tumor stage- and grade-dependent manner and associated with increased mortality in hepatocellular carcinoma.
Berkel C; Cacan E
Exp Mol Pathol; 2020 Dec; 117():104567. PubMed ID: 33171156
[TBL] [Abstract][Full Text] [Related]
2. Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer.
Berkel C; Cacan E
Biochem Biophys Res Commun; 2021 Sep; 570():74-81. PubMed ID: 34273621
[TBL] [Abstract][Full Text] [Related]
3. Upregulated mH2A1 serves as an unfavorable prognostic indicator and promotes the progress of hepatocellular carcinoma (HCC).
Yang G; Yao Y; Wu D; Guo H; Zhou S; Sun D; Guo X; Zheng T; Wang J; Zhang S; Wang Y; Song R; Ke S; Liu Y; Meng F; Liang Y; Lu Z; Liu L
Life Sci; 2020 Dec; 263():118576. PubMed ID: 33058912
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.
Duan F; Wu H; Jia D; Wu W; Ren S; Wang L; Song S; Guo X; Liu F; Ruan Y; Gu J
J Hepatol; 2018 Jun; 68(6):1191-1202. PubMed ID: 29454068
[TBL] [Abstract][Full Text] [Related]
5. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
[TBL] [Abstract][Full Text] [Related]
6. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma.
Ruan Y; Sun L; Hao Y; Wang L; Xu J; Zhang W; Xie J; Guo L; Zhou L; Yun X; Zhu H; Shen A; Gu J
J Clin Invest; 2012 Jul; 122(7):2554-66. PubMed ID: 22653060
[TBL] [Abstract][Full Text] [Related]
7. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
8. A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients.
Bedon L; Dal Bo M; Mossenta M; Busato D; Toffoli G; Polano M
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499054
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.
Sui CJ; Zhou YM; Shen WF; Dai BH; Lu JJ; Zhang MF; Yang JM
J Mol Med (Berl); 2016 Nov; 94(11):1281-1296. PubMed ID: 27380494
[TBL] [Abstract][Full Text] [Related]
10. OCIAD2 suppressed tumor growth and invasion via AKT pathway in Hepatocelluar carcinoma.
Wu D; Yang X; Peng H; Guo D; Zhao W; Zhao C; Zhou X
Carcinogenesis; 2017 Sep; 38(9):910-919. PubMed ID: 28911005
[TBL] [Abstract][Full Text] [Related]
11. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration.
Zhao W; Liu H; Liu W; Wu Y; Chen W; Jiang B; Zhou Y; Xue R; Luo C; Wang L; Jiang JD; Liu J
Int J Oncol; 2006 May; 28(5):1081-8. PubMed ID: 16596223
[TBL] [Abstract][Full Text] [Related]
12. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of circDYNC1H1 exhibits inhibitor effect on cell proliferation and migration in hepatocellular carcinoma through miR-140-5p.
Wang ZY; Zhu Z; Wang HF; Qin B; Liu J; Yao XH; Li WC; Chen KS
J Cell Physiol; 2019 Aug; 234(10):17775-17785. PubMed ID: 30864145
[TBL] [Abstract][Full Text] [Related]
14. Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma.
Liu Z; Dou C; Yao B; Xu M; Ding L; Wang Y; Jia Y; Li Q; Zhang H; Tu K; Song T; Liu Q
Oncotarget; 2016 Jun; 7(24):36909-36923. PubMed ID: 27191994
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
[TBL] [Abstract][Full Text] [Related]
16. New Insights into the Epigenetics of Hepatocellular Carcinoma.
Wahid B; Ali A; Rafique S; Idrees M
Biomed Res Int; 2017; 2017():1609575. PubMed ID: 28401148
[TBL] [Abstract][Full Text] [Related]
17. TXNDC9 promotes hepatocellular carcinoma progression by positive regulation of MYC-mediated transcriptional network.
Chen D; Zou J; Zhao Z; Tang X; Deng Z; Jia J; Liu S
Cell Death Dis; 2018 Oct; 9(11):1110. PubMed ID: 30382079
[TBL] [Abstract][Full Text] [Related]
18. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
19. Epigenomic profiling of DNA methylation for hepatocellular carcinoma diagnosis and prognosis prediction.
Zhang C; Ge S; Wang J; Jing X; Li H; Mei S; Zhang J; Liang K; Xu H; Zhang X; Zhang C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1869-1877. PubMed ID: 31038805
[TBL] [Abstract][Full Text] [Related]
20. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
